KalVista Pharmaceuticals, Inc. (KALV): Price and Financial Metrics

KalVista Pharmaceuticals, Inc. (KALV)

Today's Latest Price: $16.13 USD

0.20 (1.26%)

Updated Jan 22 4:00pm

Add KALV to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

KALV Stock Summary

  • For KALV, its debt to operating expenses ratio is greater than that reported by merely 5.4% of US equities we're observing.
  • KALV's price/sales ratio is 53.58; that's higher than the P/S ratio of 94.55% of US stocks.
  • As for revenue growth, note that KALV's revenue has grown -61.71% over the past 12 months; that beats the revenue growth of just 3.32% of US companies in our set.
  • Stocks that are quantitatively similar to KALV, based on their financial statements, market capitalization, and price volatility, are MTEM, DTIL, NXTC, FULC, and PIRS.
  • KALV's SEC filings can be seen here. And to visit KalVista Pharmaceuticals Inc's official web site, go to www.kalvista.com.

KALV Stock Price Chart Interactive Chart >

Price chart for KALV

KALV Price/Volume Stats

Current price $16.13 52-week high $20.21
Prev. close $15.93 52-week low $5.61
Day low $15.43 Volume 102,000
Day high $16.35 Avg. volume 135,164
50-day MA $17.98 Dividend yield N/A
200-day MA $13.83 Market Cap 289.40M

KalVista Pharmaceuticals, Inc. (KALV) Company Bio

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. The company is based in Cambridge, Massachusetts.

KALV Latest News Stream

Event/Time News Detail
Loading, please wait...

KALV Latest Social Stream

Loading social stream, please wait...

View Full KALV Social Stream

Latest KALV News From Around the Web

Below are the latest news stories about KalVista Pharmaceuticals Inc that investors may wish to consider to help them evaluate KALV as an investment opportunity.

Are Options Traders Betting on a Big Move in KalVista Pharmaceuticals (KALV) Stock?

Investors need to pay close attention to KalVista Pharmaceuticals (KALV) stock based on the movements in the options market lately.

Yahoo | January 11, 2021

Is KALV A Good Stock To Buy Now?

At Insider Monkey, we pore over the filings of nearly 817 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we’ve gathered as a result gives us access to a wealth of collective knowledge based on these firms’ portfolio holdings as of September 30. In this […]

Yahoo | December 17, 2020

Ascendis Pharma A/S Announces Planned Board Transition

– Chair and board member Michael Wolf Jensen will not stand for re-election at 2021 Annual General Meeting – – Board of Directors intends to appoint Dr. Albert Cha to serve as Chair after 2021 AGM –COPENHAGEN, Denmark, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced a planned board transition at the 2021 Annual General Meeting (AGM).Michael Wolf Jensen informed the Board of Directors (the Board) that he will not stand for re-election to the Board at the next Annual General Meeting. Mr. Jensen will continue in his role as Senior Vice President (SVP) and Chief Legal Officer of Ascendis. The Board intends to ap...

Yahoo | December 14, 2020

KalVista Pharmaceuticals (KALV) Catches Eye: Stock Jumps 7.4%

KalVista Pharmaceuticals (KALV) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Yahoo | December 14, 2020

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2020. “We have completed the patient treatment phase of our KVD900 Phase 2 trial and are in the process of wrapping up that study. Data from

Business Wire | December 10, 2020

Read More 'KALV' Stories Here

KALV Price Returns

1-mo N/A
3-mo 5.42%
6-mo 45.84%
1-year -5.56%
3-year 30.61%
5-year -53.73%
YTD -15.06%
2020 6.63%
2019 -9.82%
2018 102.56%
2017 37.91%
2016 -86.05%

Continue Researching KALV

Want to see what other sources are saying about KalVista Pharmaceuticals Inc's financials and stock price? Try the links below:

KalVista Pharmaceuticals Inc (KALV) Stock Price | Nasdaq
KalVista Pharmaceuticals Inc (KALV) Stock Quote, History and News - Yahoo Finance
KalVista Pharmaceuticals Inc (KALV) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9528 seconds.